Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease

American Journal of Gastroenterology

Volumn 98, Issue 3 SUPPL., 2003, Pages

  Bardhan, Karna Dev ^a  

^a Rotherham NHS Foundation Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

BARRETT ESOPHAGUS; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; EVALUATION; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REFLUX ESOPHAGITIS; RELAPSE; TREATMENT OUTCOME;

EID: 0037343840     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(03)00014-5     Document Type: Conference Paper

References (50)

1. Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol 1999;231(suppl):20-8.
2. Tougas G, Chen Y, Hwang P, et al. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Domestic/International Gastroenterology Surveillance Study. Am J Gastroenterol 1999;94:2845-54.
3. Locke GR III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-56.
4. A Gallup Organization National Survey. Heartburn Across America. Princeton, NJ: Gallup Organization, 1988.
5. Galmiche JP, Barthelmey P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-73.
6. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9.
7. Hungin APS, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999;49:463-4.
8. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.
9. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988;23:625-32.
10. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazology. Gastroenterology 1988;95:903-12.
11. Holt AP, Walt RP. Preventing GORD relapse: the evidence. Int J Gastroenterology 2001;5:9-14.
12. Dent J. Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux esophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994;34:590-8.
13. 2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment. Ital J Gastroenterol Hepatol 1997;29:515-9.
14. Hungin APS, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999;49:451-3.
15. Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut 2002;50:460-4.
16. Bank S, Magier D, Greenberg R, Blumstein M. Alternate day omeprazole maintenance therapy in H2RA resistant esophagitis: clinical, gastrin and ECL effects for up to 3 years (abstract). Gastroenterology 1992;102:A35.
17. Bank S, Greenberg R, Blumstein M, et al. "Spaced" omeprazole dosing in maintenance therapy of H2RA resistant reflux esophagitis: results from 6 to 48 months (abstract). Gastroenterology 1993;104:A38.
18. Rubin GP, Contractor B, Bramble MG. The use of long-term acid suppression therapy. Br J Clin Pract 1995;49:119-20.
19. Poynard T. Relapse rate of patients after healing of oesophagitis: a prospective study of alginate as self-care treatment for 6 months. French Co-operative Study Group. Aliment Pharmacol Ther 1993;7:385-92.
20. Bardhan KD. Intermittent treatment of duodenal ulcer with cimetidine. Br Med J 1980;281:20-2.
21. Heading RC. Long-term management of gastroesophageal reflux disease. Scand J Gastroenterol 1995;30(Suppl 213):25-30.
22. Bieszk N, Kale-Pradhan PB. The efficacy of extended-interval dosing of omeprazole in keeping gastroesophageal reflux disease patients symptom free. Ann Pharmacother 1999;33:638-41.
23. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999;44(Suppl 2):S1-16.
24. Nathoo V. Managing gastro-oesophageal reflux disease in primary care. Int J Clin Pract 2001;55:465-9.
25. Bytzer P. On-demand therapy for gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2001;13(suppl 1):S19-22.
26. National Institute for Clinical Excellence. Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. NHS Technology Appraisal Guidance No 7. July 2000.
27. Bardhan KD, Müller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. Br Med J 1999;318:502-7.
28. Stålhammar NO, Carlsson J, Peacock R, et al. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. Pharmacoeconomics 1999;16:483-97.
29. Bardhan KD. Omeprazole in the treatment of gastroesophageal reflux disease. In: Scarpignato C. (ed). Advances in Drug Therapy of Gastroesophageal Reflux Disease. Basel, Karger. Front Gastroint Res 1992;20:246-306.
30. Lind T, Havelund T, Lundel S, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999;13:907-14.
31. Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopically negative GERD. A placebo controlled trial of on-demand therapy for 6 months (abstract). Gastroenterology 2000;118:A658.
32. Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001;96:1998-2004.
33. Wiklund I, Bardhan KD, Müller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol 1998;30:19-27.
34. Scholten T, Gatz G, Sander P. On-demand therapy with pantoprazole 20 mg od for the long-term management of GERD patients previously healed from heartburn (abstract). Gut 2001;49(Suppl 3):A64.
35. Langman MJS. Which PPI? Gut 2001;49:309-10.
36. Pantoflickova D, Dorta G, Jornod P, et al. Identification of the characteristics influencing the degree of antisecretory activity in PPIs (abstract). Gastroenterology 2000;118(Suppl 2): A1290.
37. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998;12:1079-89.
38. Thompson ABR, Claar-Nilsson C, Hasselgren G, et al. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration (abstract). Gut 2000;47(Suppl 3):A63.
39. Röhss K, Claar-Nilsson C, Rydholm H, Nyman L. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg (abstract). Gastroenterology 2000;118:A20.
40. Huang JQ, Goldwater DR, Thomson ABR, et al. Acid suppression in healthy subjects following lansoprazole or pantoprazole. Aliment Pharmacol Ther 2002;16:425-33.
41. US Prescribing Information 2001. Currently available proton pump inhibitors. Comparison of day 1 pharmacokinetics. Available at: www.powerpak.com/CE/protonpump/pharmacy/tables.cfm.
42. Warrington S, Baisley K, Boyce M, et al. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002;16:1301-7.
43. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patients symptomatology and quality of life. Gut 1996;38:481-6.
44. Ollyo JB, Monnier P, Fontolliet C, Savary M. The natural history, prevalence and incidence of reflux oesophagitis. Gullet 1993;3(Suppl):3-10.
45. Bardhan KD, Royston C, Nayyar AK. Reflux rising! A disease in evolution? (abstract). Gastroenterology 2000;118:A478.
46. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
47. Ho KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am J Gastroenterol 1998;93:1816-22.
48. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. N Engl J Med 1992;326:786-92.
49. McRea H. The world in 2020. Power, culture and prosperity. New York: Harper Collins, 1994.
50. Eberstadt N. World population implosion? Public Interest 1997;Fall:3-22.